Rimeporide is primarily investigated for its potential therapeutic applications in treating various medical conditions, particularly those involving tissue injury and inflammation. It functions as a sodium-hydrogen exchanger inhibitor, which plays a role in reducing cellular damage and inflammation. One of the key areas of research for rimeporide is its use in treating Duchenne muscular dystrophy (DMD). Studies suggest that it may help mitigate muscle degeneration and inflammation associated with this genetic disorder, potentially improving muscle function and slowing disease progression. Additionally, rimeporide has been explored for its cardioprotective effects. It may reduce myocardial injury and improve outcomes in conditions such as heart failure or after a heart attack by limiting inflammation and cell death in cardiac tissues. Research also indicates potential applications in other inflammatory and fibrotic diseases, such as pulmonary fibrosis or kidney injury, where its anti-inflammatory and anti-fibrotic properties could provide therapeutic benefits. Overall, rimeporide represents a promising candidate for addressing a range of conditions characterized by tissue damage and inflammation, though further clinical studies are needed to confirm its efficacy and safety.